Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBLG Bone Biologics	$2.93 +0.3%	$4.46	$2.86 ▼ $25.50	$1.61M	0.69	352,571 shs	2,906 shs
IVF INVO Fertility	$0.83 -0.1%	$1.27	$0.74 ▼ $17.04	$1.79M	2.04	1.14 million shs	4,013 shs
LGMK LogicMark	$0.00 -9.4%	$0.01	$0.00 ▼ $15.35	$1.67M	1.48	50.04 million shs	21.16 million shs
SONX Sonendo	$1.15	$1.23	$1.00 ▼ $17.00	$493K	1.5	1,012 shs	1 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBLG Bone Biologics	-1.35%	-3.31%	-42.52%	-28.43%	-57.31%
IVF INVO Fertility	+1.15%	+1.13%	-33.66%	+82,929,900.00%	+82,929,900.00%
LGMK LogicMark	-9.38%	-9.38%	-23.68%	-69.15%	-99.98%
SONX Sonendo	0.00%	0.00%	0.00%	-7.26%	+1,387.71%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBLG Bone Biologics	0.7436 of 5 stars	0.0	2.0	0.0	0.0	3.3	0.0	1.3
IVF INVO Fertility	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LGMK LogicMark	0.1333 of 5 stars	0.0	3.0	0.0	0.0	0.0	0.0	0.6
SONX Sonendo	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBLG Bone Biologics	N/A	N/A	N/A
IVF INVO Fertility	N/A	N/A	N/A
LGMK LogicMark	N/A	N/A	N/A
SONX Sonendo	N/A	N/A	N/A

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBLG Bone Biologics	N/A	N/A	N/A	N/A	$8.39 per share	N/A
IVF INVO Fertility	$6.53M	0.27	N/A	N/A	($29.86) per share	-0.03
LGMK LogicMark	$9.88M	0.17	N/A	N/A	$148.65 per share	0.00
SONX Sonendo	$44.40M	0.01	N/A	N/A	$89.42 per share	0.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBLG Bone Biologics	-$4.11M	N/A	0.00	N/A	N/A	N/A	-130.21%	-119.39%	8/8/2025 (Estimated)
IVF INVO Fertility	-$9.10M	-$34.06	N/A	∞	N/A	-377.73%	N/A	-88.18%	N/A
LGMK LogicMark	-$14.55M	-$223.50	N/A	∞	N/A	-141.96%	-124.91%	-92.05%	8/12/2025 (Estimated)
SONX Sonendo	-$60.92M	-$59.12	N/A	∞	N/A	-92.74%	-184.01%	-68.60%	8/8/2025 (Estimated)

Latest SONX, LGMK, IVF, and BBLG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LGMK LogicMark	-$0.03	N/A	N/A	N/A	$2.35 million	N/A
8/8/2025	N/A	BBLG Bone Biologics	-$1.93	N/A	N/A	N/A	N/A	N/A
5/20/2025	Q1 2025	IVF INVO Fertility	N/A	-$12.53	N/A	-$12.53	N/A	$1.64 million
5/15/2025	Q1 2025	LGMK LogicMark	-$0.03	-$0.12	-$0.09	-$0.12	$2.23 million	$2.59 million
5/12/2025	Q1 2025	BBLG Bone Biologics	-$2.88	-$1.92	+$0.96	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBLG Bone Biologics	N/A	N/A	N/A	N/A	N/A
IVF INVO Fertility	N/A	N/A	N/A	N/A	N/A
LGMK LogicMark	N/A	N/A	N/A	N/A	N/A
SONX Sonendo	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBLG Bone Biologics	N/A	12.60	12.60
IVF INVO Fertility	N/A	0.08	0.07
LGMK LogicMark	N/A	3.73	3.29
SONX Sonendo	0.55	1.82	1.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBLG Bone Biologics	34.30%
IVF INVO Fertility	12.02%
LGMK LogicMark	7.88%
SONX Sonendo	28.68%

Insider Ownership

Company	Insider Ownership
BBLG Bone Biologics	6.10%
IVF INVO Fertility	0.57%
LGMK LogicMark	2.17%
SONX Sonendo	7.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBLG Bone Biologics	2	550,000	512,000	Not Optionable
IVF INVO Fertility	10	2.16 million	2.15 million	N/A
LGMK LogicMark	20	576.31 million	2.65 million	No Data
SONX Sonendo	250	429,000	393,000	Not Optionable

SONX, LGMK, IVF, and BBLG Headlines

Recent News About These Companies

Sonendo, Inc. Reports First Quarter 2025 Financial Results and Issues Financial Guidance

June 4, 2025 | businesswire.com

Sonendo Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

March 26, 2025 | businesswire.com

Sonendo, Inc. to Release Third Quarter 2024 Financial Results and Postpone Conference Call on November 12, 2024

November 11, 2024 | businesswire.com

Sonendo, Inc. (SONX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

November 5, 2024 | zacks.com

Sonendo Launches ProControlTM for the GentleWave® G4 System

October 23, 2024 | businesswire.com

Sonendo, Inc. Announces Preliminary Third Quarter 2024 Financial Results

October 10, 2024 | businesswire.com

BIOLASE files for Chapter 11, plans asset sale to Sonendo

October 3, 2024 | investing.com

Here's Why Sonendo (SONX) Is a Great 'Buy the Bottom' Stock Now

August 27, 2024 | zacks.com

Sonendo Inc.

August 17, 2024 | marketwatch.com

Sonendo, Inc. (SONX) Q2 2024 Earnings Call Transcript

August 10, 2024 | seekingalpha.com

Sonendo, Inc. (SONX) Reports Q2 Loss, Tops Revenue Estimates

August 7, 2024 | zacks.com

Sonendo, Inc. Reports Second Quarter 2024 Financial Results and Raises Full Year Revenue Guidance

August 7, 2024 | finance.yahoo.com

Here's what Wall Street expects from Sonendo's earnings report

August 7, 2024 | markets.businessinsider.com

Sonendo, Inc. (SONX)

July 28, 2024 | finance.yahoo.com

Sonendo Strengthens Leadership With Key Strategic Appointments

June 5, 2024 | businesswire.com

Sonendo to Present at the 2024 Stifel Jaws & Paws Conference

May 20, 2024 | businesswire.com

Sonendo, Inc. (SONX) Q1 2024 Earnings Call Transcript

May 12, 2024 | seekingalpha.com

Sonendo, Inc. (NYSE:SONX) Q1 2024 Earnings Call Transcript

May 12, 2024 | msn.com

Sonendo Inc (SONX) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and Financial ...

May 9, 2024 | finance.yahoo.com

SONX Stock Earnings: Sonendo Misses EPS, Beats Revenue for Q1 2024

May 8, 2024 | investorplace.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SONX, LGMK, IVF, and BBLG Company Descriptions

Bone Biologics NASDAQ:BBLG

$2.93 +0.01 (+0.34%)

As of 09:45 AM Eastern

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

INVO Fertility NASDAQ:IVF

$0.83 0.00 (-0.10%)

As of 09:09 AM Eastern

NAYA Biosciences (NASDAQ: NAYA) is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. Our hub & spoke model harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. NAYA’s expanding portfolio of assets currently includes NY-303, a GPC3 and NKp46 targeting bispecific antibody for the treatment of hepatocellular carcinoma (HCC) with a unique mode of action targeting non-responders to the current immunotherapy standard of care (approximately 70% of the current treatable market) cleared to enroll patients in a Phase I/II monotherapy trial in early 2025, NY-338, a CD38 and NKp46 targeting bispecific antibody for the treatment of multiple myeloma and autoimmune diseases with a differentiated safety and efficacy profile, and INVOcell®, an FDA-approved fertility device which has demonstrated comparable success rates to traditional In Vitro Fertilization (IVF).

LogicMark NASDAQ:LGMK

$0.0029 0.00 (-9.38%)

As of 07/17/2025 03:57 PM Eastern

LogicMark, Inc. provides personal emergency response systems (PERS), health communications devices, and Internet of Things (IoT) technology that creates a connected care platform in the United States. The company's devices provide people with the ability to receive care at home and age independently and to check, manage, and monitor a loved one's health and safety remotely. It also manufactures and distributes non-monitored and monitored personal emergency response systems, which are offered through the United States Veterans Health Administration (VHA), direct-to-consumers, healthcare durable medical equipment dealers and distributors, monitored security dealers and distributors, and its ecommerce website logicmark.com and Amazon.com. The company was formerly known as Nxt-ID, Inc. and changed its name to LogicMark, Inc. in March 2022. LogicMark, Inc. was founded in 2006 and is based in Louisville, Kentucky.

Sonendo NYSE:SONX

$1.15 0.00 (0.00%)

As of 07/16/2025

Sonendo, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment, a technology platform designed for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The company also offers SoundSeal, a material used to build and create a sealing platform on the top of the crown; and Sonendo-branded liquid solution of ethylenediaminetetraacetic acid EDTA that is used to help debride and disinfect the root canal system. In addition, it provides The Digital Office, a practice management software to enable an integrated digital office for dental practitioners. The company was formerly known as Dentatek Corporation and changed its name to Sonendo, Inc. in March 2011. The company was incorporated in 2006 and is headquartered in Laguna Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time